Associate Professor, Department of Medicine and Department of Epidemiology, Biostatistics, and Occupational Health, McGill University
Investigator, Center for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital
Professor Filion is an Associate Professor in the Departments of Medicine (Division of Clinical Epidemiology) and of Epidemiology, Biostatistics, and Occupational Health at McGill University and a Principal Investigator at the Center for Clinical Epidemiology of the Lady Davis Institute. He obtained his PhD in Epidemiology from McGill's Department of Epidemiology, Biostatistics, and Occupational Health and completed his post-doctoral training in Cardiovascular Epidemiology at the Division of Epidemiology and Community Health of the University of Minnesota.
Major Research Activities
Professor Filion's research interests include pharmacoepidemiology and drug safety, knowledge synthesis, and cardiovascular epidemiology. He uses large, population-based databases to study the safety of commonly prescribed medications, with a particular interest in cardiovascular medications and cardiovascular outcomes. He is the Co-Lead of the Clinical Practice Research Datalink (CPRD) Team of the Canadian Network for Observational Drug Effect Studies (CNODES), a pan-Canadian drug safety network funded by the Canadian Institutes of Health Research. In addition, Professor Filion is involved in a number of systematic reviews and meta-analyses examining the efficacy and safety of cardiovascular therapies.
Recent Publications
Filion KB,
Azoulay L, Platt RW, Dahl M, Dormuth CR, Clemens KK, Hu N, Paterson JM,
Targownik L, Turin TC, Udell JA, Ernst P for the Canadian Network for
Observational Drug Effect Studies (CNODES) Investigators. A multicenter
observational study of incretin-based drugs and heart failure. N Engl J
Med 2016; 374:1145-54. [Press release]
Filion KB, Lix LM, Yu OH, Dell'Aniello S, Douros A, Shah BR, St-Jean A, Fisher A, Tremblay E, Bugden SC, Alessi-Severini S, Ronksley PE, Hu N, Dormuth CR, Ernst P, Suissa S; Canadian Network for Observational Drug Effect Studies (CNODES) Investigators. Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study. BMJ. 2020;370:m3342. doi: 10.1136/bmj.m3342.
Douros A, Lix LM, Fralick M, Dell'Aniello S, Shah BR, Ronksley PE, Tremblay É, Hu N, Alessi-Severini S, Fisher A, Bugden SC, Ernst P, Filion KB. Sodium-glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis : a multicenter cohort study. Ann Intern Med. 2020;173:417-425. doi: 10.7326/M20-0289.